Dupixent & T-Cell Lymphoma Claims

What happened

Dupixent (dupilumab) is a widely prescribed biologic injection for atopic dermatitis (eczema), asthma, and related inflammatory conditions. Recent studies and case reports have associated Dupixent use with an increased risk of cutaneous T-cell lymphoma (CTCL), a cancer of the immune system that appears in the skin. Researchers are examining whether the drug promotes lymphoma progression or unmasks previously undiagnosed disease that was mistaken for stubborn eczema.

Who may qualify

• Used Dupixent for eczema, asthma, or another condition, and
• Were later diagnosed with T-cell lymphoma, including mycosis fungoides or Sézary syndrome

What to do

Keep your prescription records and pathology reports, and get a free case review. If your claim is better suited to national litigation, we associate experienced co-counsel while remaining your local point of contact.